Lacticaseibacillus paracasei

Lpc-37®

In this section

  • Our signature strains
Grant JR, Stothard P. The CGView Server: a comparative genomics tool for circular genomes. Nucleic Acids Res. 2008;36:W181-W184.

Lpc-37® introduction

Lacticaseibacillus paracasei Lpc-37®, previously known as Lactobacillus paracasei Lpc-37®, has been studied alone or in combination with other strains. It is frequently studied alongside of NCFM®, Bi-07™, and Bl-04® as part of the HOWARU® Restore blend for digestive health.1 Lpc-37® has also been studied for its impact on managing the psychological response to stress.2 Lpc-37® has been cited in more than 60 scientific publications, including more than 18 clinical trials. It has a long history of safe use, is well suited for intestinal survival, and has strong adhesion to intestinal cell lines and pathogen inhibition.3,4 

43 In vitro through product functionality studies

+18

Clinical trials

VERIFY protocol
quality and safety

HEALTH-BENEFIT AREA SUPPORTED DOSING (CFU) STUDY REFERENCE
Dysbiosis restoration 17 billion (equal parts) Lpc-37®, Bi-07™, NCFM®, Bl-04® Ouwehand AC, et al. Vaccine. 2014;32(4):458-463.
Gut-Brain health 17 billion Lpc-37® Patterson E, et al. Neurobiol Stress. 2020;13:100277.

For additional information, visit our Lpc-37® bibliography

Read more about Lpc-37®
REFERENCES:
1. Ouwehand AC, DongLian C, Weijian X, et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine. 2014;32:458-463. 2. Patterson E, Griffin SM, Ibarra A, Ellsiepen E, Hellhammer J. Lacticaseibacillus paracasei Lpc-37® improves psychological and physiological markers of stress and anxiety in healthy adults: a randomized, double-blind, placebo-controlled and parallel clinical trial (the Sisu study). Neurobiol Stress. 2020;13:100277. doi: 10.1016/j.ynstr.2020.100277. 3. Ding WK, Shah NP. Acid, bile and heat tolerance of free and microencapsulated probiotic bacteria. J Food Sci. 2007;72:M446-450. 4. Gibson GR, McCartney AL, Rastall RA. Prebiotics and resistance to gastrointestinal infections. Br J Nutr. 2005;93(Suppl. 1):S31-34.

QUICK LINKS

Home

Probiotics – Know IFF

About Probiotics

The Howaru® Difference

Health Benefit Areas

Careers

Vendors

Control Reports

ESG

Investor Relations

Sitemap

STAY IN TOUCH

Keep up to date on social media

Linkedin Youtube Weixin Facebook Twitter Instagram
 

Copyright © 2023 by International Flavors & Fragrances Inc. IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted.

The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.
ARE YOU A HEALTHCARE PROFESSIONAL?
YES
NO